Fig. 7: Specific immune responses distinguish Coxevac®, QuilA®-Coxevac® and control goats following C. burnetii challenge. | npj Vaccines

Fig. 7: Specific immune responses distinguish Coxevac®, QuilA®-Coxevac® and control goats following C. burnetii challenge.

From: QuilA® adjuvanted Coxevac® sustains Th1-CD8+-type immunity and increases protection in Coxiella burnetii-challenged goats

Fig. 7: Specific immune responses distinguish Coxevac®, QuilA®-Coxevac® and control goats following C. burnetii challenge.The alternative text for this image may have been generated using AI.

a Principal component analysis (PCA) of the complete dataset (n = 68), which included data from serology (weeks 13.5, 17.5 and 19 pv), IFNγ secretion upon antigen specific stimulated PBMCs (weeks 13.5, 17.5 and 19 pv), organ and blood (week 19 pv) phenotyping and gene expression profiles. b PCA of specific selected variables (n = 22) resulting in an accurate separation of the three conditions. From the left, graph 1 is the 2D PCA score plot of the first two components (a, b). Symbols represent animals, the central one corresponds to the mean coordinates of the individuals in the group. Graph 2 is the PCA loading plot showing the distribution of all 22 variables (b) or of variables with a contribution more than 1.5 (n = 31, the loading plot containing all 68 variables is shown in Supplementary Fig. 5) (a). Graph 3 is the 3D PCA score plot of the first three components, realized to increase the proportion of variance illustrated by the analysis (a, b). B=blood, S=spleen, BL=bronchial lymph nodes, IL=inguinal lymph nodes, PH=phenotyping, W=week, Contrib=contribution.

Back to article page